摘要
目的评估拉米夫定联合主被动免疫对阻断HBV母婴传播的疗效。方法对HBV感染的孕妇随机分为4组,分别给予拉米夫定、HBIG、拉米夫定和HBIG治疗、同时设不治疗为对照组,分别用ELISA、定量PCR检测孕28周及分娩前孕妇HBV血清标志物及HBV DNA含量,以及新生儿、12个月婴儿血清HBV标志物、HBV DNA含量。结果拉米夫定、HBIG、拉米夫定和HBIG治疗与对照组相比,可显著降低孕妇血HBV DNA水平(P<0.01),降低新生儿宫内感染率(P<0.001),增强12个月婴儿抗-HBs阳转率及抗体滴度。结论拉米夫定及HBIG均可有效阻断HBV母婴垂直传播,减少婴幼儿HBV感染。
Objective To evaluate the therapeutic effect of lamivudine treatment and active-passive immunization for pregnant women in preventing HBV infection.Methods Women with HBV infection were fractionated to lamivudine group,HBIG group,lamivudine combined HBIG group,and control group randomly,and were detected the HBV infection and HBV DNA levels at 28-weeks’ gestation and ante partum by ELISA and quantitation PCR.Serum HBV marker and HBV DNA of newborn infant and 12-months’ infants were investigated.Results Compare to control group,lamivudine,HBIG,and lamivudine combined HBIG can significantly decrease the HBV DNA levels in pregnant women(P<0.01),diminish the intrauterine infection rates of HBV( P<0.001),increase the positive seroconversion rates of anti-HBs and antibody titre at 12-months’ infants.Conclusion Lamivudine and HBIG effectively block the vertical transmission of HBV,diminish the HBV infection in infants.
出处
《中国实用医药》
2007年第13期14-16,共3页
China Practical Medicine
